BioTech-World · Werben · Kontakt · BTW-Startseite  

1 - AdEasy 2 - AdEasy 3 - AdEasy

 

Bestellen Sie den kostenlosen BioTech-World Letter. E.Mail:

Buchempfehlung

Investieren in Biotech- Aktien


Profi- Handbuch Pharma- und Biotech- Aktien

















News News USA Biotech-Nachrichten


16.01.
Aldurazyme Moves Forward

15.01.
Replagal’s Final Blow

15.01.
Fabrazyme Closer to Orphan Exclusivity

09.01.
Ketek Recommended by FDA Advisory Committee

09.01.
Mixed Actimmune Data

07.01.
BioBypass Disappoints

07.01.
BiotechTracker Profile of Amgen

07.01.
Rituxan for Hodgkin Disease

06.01.
OSI Pharmaceuticals Announces Appointment of Mr. Robert A. Ingram as Chairman of the Board;Announces Board, Committee and Governance Changes

03.01.
Too Many Cooks Spoil the Drug-Coated Stent

02.01.
Publication Confirms Impact of Antegren on Brain Lesions in Multiple Sclerosis Patients

24.12.
Raptiva BLA Filed

20.12.
Study Should Lead to Increased Use of Natrecor

20.12.
Xolair BLA Re-Submitted

20.12.
ALLHAT Studies will Impact Use of Non-Thiazides More than Use of Statins

19.12.
ILEX Begins Phase I/II Trial ofCAMPATH in Non-Hodgkins Lymphoma; Study Findings Will GuideSubsequent Combination Therapy Trials

19.12.
Advanced Tissue Sciences ProvidesBankruptcy Update

19.12.
JP Morgan H&Q Healthcare Conference toWebcast Alkermes´ Corporate Presentation

19.12.
Novartis Wins Wider FDA Approval for Clozaril, Amends Xolair Application with FDA

19.12.
Committee Recommends Termination of Phase3 Study of Pafase -- rPAF-AH -- in Severe Sepsis

19.12.
Nature Medicine Article HighlightsDevelopment of Regeneron´s Cytokine Trap Technology

19.12.
Genentech and Novartis Submit Amendment tothe Biologics License Application for Xolair -- Omalizumab -- to FDA

19.12.
ILEX to Sublicense CAMPATH DiagnosticRights for Hematologic Diseases to U.K.-Based BioAnaLab for EuropeanMarkets

19.12.
Interim Data Support ISIS-2503 Development

19.12.
Bexxar Receives Positive ODAC Review

10.12.
Exanta and Arixtra Shine at ASH

10.12.
Genasense Activity Confirmed in Phase I and II Trials, but Physician Interest Low

04.12.
Exanta at ASH

04.12.
Velcade at ASH

03.12.
Bexxar Will Get Its Second Chance with the FDA

03.12.
Eprex Safety Concerns Continue to Benefit Amgen

03.12.
ASH Preview

27.11.
Forteo Approved

27.11.
Another Replagal Setback

27.11.
Suboptimal Study Suggests Rebif Advantage Over Avonex

27.11.
Zavesca Approved in Europe

25.11.
Aldurazyme Should be Approved

21.11.
Study Supports BioBypass Development

21.11.
Onyx’s Raf Inhibitor Shows Promise

21.11.
Boston Scientific Presents Additional Coated Stent Data

19.11.
Treatment Regimen for Pexelizumab Starting to Take Shape

15.11.
FDA Committee Recommends Pegasys / Copegus Combo

14.11.
Prodrugs and Improved Drug Delivery for Parkinson Disease

13.11.
FDA Committee Will Review Pegasys / Copegus Combination

13.11.
Advantages of the Zevalin Therapeutic Regimen

12.11.
Hyseq / Variagenics Combined Company May Still Lack Critical Mass

08.11.
No Label Expansion for Copaxone into PPMS

08.11.
Seattle Genetics’ Clinical Pipeline is Not Its Most Compelling Asset

06.11.
Bexxar Round II

06.11.
New Xigris Data Only a Beginning

05.11.
AMG073 Moves Forward

29.10.
Modest Pralnacasan Results in Rheumatoid Arthritis

29.10.
Reminyl Fails to Meet Primary Endpoint

29.10.
Exelixis / Glaxo Deal May Signal the Return of Platform Technologies

29.10.
Interleukin Profiles RA Patients

29.10.
Upcoming FDA Advisory Panel Meetings

29.10.
EXPRESS Results

27.10.
Prodrug Protease Product Produces Profound Progress

22.10.
Sitaxsentan May Stack Up Well Against Other Pulmonary Arterial Hypertension Treatments

22.10.
Maxim Continues to Gain Back Lost Ground

19.10.
Adverse Event Concerns for Hemopure Recipients

19.10.
Glivec (Gleevec) Sales Should Increase In the U.K.

15.10.
Prospects for Exubera

11.10.
Study May Lead to Increased Use of Activase

09.10.
Endovasc - Company with Two Potential Blockbuster Cardiovascular Drugs Approved for FDA Phase III Trials - Expands on Its Future Revenue Model on BioBusiness Networks

08.10.
Results of Phase 1 Albutropin(TM) Trial Demonstrate Safety, Prolonged Half-Life, and Biological Activity

08.10.
Seattle Genetics Provides Update On SGN-14

08.10.
Cephalon Quarterly Conference Call Invitation

08.10.
Biomerica Launches New FDA Cleared Calcitonin Test in U.S. and Europe

08.10.
Targeted Genetics Receives $4 Million in Equity Funding Under Collaboration With Biogen

07.10.
License from MIT expands and strengthens high-throughput platform capabilities

07.10.
Versicor Announces Completion of Pivotal Phase III Study of Anidulafungin For Esophageal Candidiasis

07.10.
IDEC Pharmaceuticals Extends Subscription to Gene Logic's GeneExpress Oncology DataSuite

07.10.
Cell Therapeutics, Inc. Initiates Phase III Clinical Trial of XYOTAX(TM) For Second-Line Treatment of Non-Small Cell Lung Cancer

07.10.
Celera Diagnostics Announces Collaboration With Bristol-Myers Squibb to Study Cardiovascular Disease and Diabetes

04.10.
Results of Phase III Clinical Trial Reveal Estrasorb(TM) (Estradiol

04.10.
MORNING UPDATE: Man Securities Issues Alerts for MEDI

04.10.
Lexicon Genetics Discovers New Role for Protein to Develop Antibody For Treatment of Inflammation

03.10.
Versicor to Present at Annual UBS Warburg Global Life Science Conference

03.10.
Sepracor Inc. Sets Conference Call and Webcast For Third Quarter 2002 Results

03.10.
Zacks Issues Buy Recommendations on the Following 4 Stocks: GILD ...

03.10.
Chugai Pharmaceutical Files XYOTAX Investigational New Drug Application To Support Initiation of Clinical Trials in Japan

03.10.
Zacks Issues Sell Recommendations on the Following 4 Stocks: CELG,...

02.10.
Positive Resten-NG Results

02.10.
Rituxan for Rheumatoid Arthritis

02.10.
Positive rhuFab V2 Results

27.09.
More Positive Coated Stent Data

25.09.
Deciphering Cypher Data

25.09.
Iressa Squeezes Through

25.09.
Genmab Cancels HuMax-CD4 RA Development

24.09.
Aphton Corporation's (APHT) Drug G17DT Gets FDA Fast-Track Designation

24.09.
Roche And KOSAN Biosciences (KOSN) To Jointly Develop And Commercialize Kosan's Epothilone D As An Anti-Cancer Agent; Roche To Pay $220 Million

24.09.
FDA Approves Gilead Sciences' (GILD) Hepsera For The Treatment Of Chronic Hepatitis B

24.09.
Memantine Application Delayed

24.09.
FDA Concerns in Advance of Iressa Meeting

24.09.
Tarceva Trial Changes

04.09.
Genentech Names Stephen G. Juelsgaard Executive Vice President

04.09.
Onyx and Bayer Initiate Phase II Studies of Raf Kinase Inhibitor

23.08.
"NEW" ALZHEIMER DRUG FROM MYRIAD

20.08.
DISAPPOINTING IRESSA RESULTS

16.08.
NO EVIDENCE THAT PREOS INCREASES CANCER RISK

14.08.
GLIVEC (GLEEVEC) USE LIKELY TO INCREASE IN U.K.

07.08.
CRESTOR APPROVAL CONCERNS

06.08.
Kos Reports Record Revenue, Prescriptions and Market Share

06.08.
Novavax to Report Second Quarter 2002 Financial Results

06.08.
VaxGen Releases Second-Quarter Financial Results

06.08.
PhotoPoint PDT Targets Both Tumor Cells and Blood Vessels in Preclinical Breast Cancer Study

05.08.
Gilead Announces Posting of FDA Briefing Documents for August 6 Advisory Committee Review of Adefovir Dipivoxil for Chronic Hepatitis B

05.08.
THE MOUSE GENOME REVEALED

02.08.
StemCells, Inc. Announces Second Quarter 2002 Financial Results

02.08.
Genentech and XOMA Announce Preliminary Data From Long-term Study With Investigational Psoriasis Therapy

02.08.
MEMANTINE NDA

01.08.
Will The Market Reverse Lower?

01.08.
Cell Therapeutics, Inc. Initiates First Phase II XYOTAX(TM) Study

01.08.
Tarceva U.S. Phase III Non-Small Cell Lung Cancer Clinical Trial Completes Patient Enrollment

31.07.
Enzon Announces Fourth Quarter and Year-end Fiscal 2002 Conference Call

31.07.
Onyx Pharmaceuticals Reports Second Quarter and Six Months Financial Results

31.07.
ARIAD Reports Second Quarter 2002 Results

31.07.
Antigenics' Heat Shock Protein Technology Platform Expanded

31.07.
GUIDANT ACQUIRES COOK & VERNALIS AND ROCHE CANCEL DEVELOPMENT OF OBESITY DRUG

30.07.
Applied Biosystems Signs Global Reseller Agreement with geneticXchange for discoveryHub Middleware Technology

30.07.
Dyax Corp. Announces Second Quarter 2002 Financial Results

30.07.
Kosan Announces Issuance of Key US Patents for Ketolide Anti-Infective Agents

30.07.
Schaeffer's Option Activity Watch Features ENZN, KFT, LU

25.07.
VARDENAFIL APPROVABLE

24.07.
EXPANSION OF STATINS AND NSAIDS TO ALZHEIMER TREATMENT

24.07.
MEMANTINE FOR ALZHEIMER DISEASE

24.07.
GENOMICS DERIVED DRUG ENTERS CLINICAL TRIALS

24.07.
NEW NITRIC OXIDE THERAPEUTICS

24.07.
ALZHEIMER DISEASE THERAPEUTICS AFTER BETABLOC

24.07.
INFUSE BONE GRAFT APPROVED

24.07.
THE FDA WILL RE-EXAMINE BEXXAR

24.07.
A STATIN A DAY KEEPS THE DOCTOR AWAY

24.07.
MOLECULAR CLASSIFICATION OF DISEASE

24.07.
SETBACK FOR VEVESCA APPROVAL



Bitte waehlen Sie aus der Uebersicht!


Copyright 2001 BioTech-World. All Rights Reserved. | Impressum | Disclaimer |